ConductScience.org, home

Comparison · NCT04533737-deaths

Arm 1 (Brodalumab + Dummy 1) vs Arm 2 (Guselkumab + Dummy 2): deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Arm 1 (Brodalumab + Dummy 1) vs Arm 2 (Guselkumab + Dummy 2): deaths from any cause. Trial comparisons, record NCT04533737-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04533737-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.000000000000000006940.0642wilson
Risk in group 200.000000000000000006940.0642wilson
Risk difference, group 1 minus group 20-0.06420.0642newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Arm 1 (Brodalumab + Dummy 1)
Participants receive:~* Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~* Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks.~Brodalumab: Pre-filled syringe with 210 mg brodalumab in 1.5 ml solution for subcutaneous injection.~Placebo: The placebo solution is similar to the active guselkumab solution except that it does not contain any active substance.
056EG000
Group 2Arm 2 (Guselkumab + Dummy 2)
Participants receive:~* Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~* Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~Guselkumab: Pre-filled syringe with 100 mg guselkumab in 1 ml solution for subcutaneous injection.~Placebo: The placebo solution is similar to the active brodalumab solution except that it does not contain any active substance.
056EG001

Harm

What it counts
Total, all-cause mortality
Time frame
28 Weeks

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
NCT number
NCT04533737
Phases
PHASE4
Conditions
Plaque Psoriasis, Psoriasis Vulgaris, Psoriasis
Interventions
Brodalumab, Placebo, Guselkumab
Lead sponsor
LEO Pharma
Results first posted
2024-01-09

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04533737-deaths